ReviewMultiple sclerosis (Houndmills, Basingstoke, England)2018

Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.

Elizabeth A Mills et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.